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Introduction
Major depressive disorder (MDD) remains one of
the most frequently seen psychiatric illnesses in pri-
mary care settings (1). Although family and primary
care physicians have greatly increased their recogni-
tion and treatment of this illness, MDD remains an
unresolved treatment challenge for many physicians
and patients (2). Increasing evidence has accrued in
recent years regarding the impact of MDD on the
structural and functional processes occurring in the
brain. From the initial views that depression was
caused by ‘chemical imbalance’ in the brain, this
body of research has developed into a complex the-
ory involving neuronal networks and plasticity (3).
The network model has also led to a greater under-
standing of the mechanisms of effective treatment
interventions and their role in mitigating the delete-
rious effects of MDD (4).
The objectives of the present review were to sum-
marise the key ﬁndings from the clinical literature
regarding the neurobiology of MDD and their impli-
cations for maximising treatment outcomes. First,
the evidence that MDD is not only a chronic and
recurrent illness, but also a progressive illness will be
presented. Second, the impact of MDD on the pri-
mary neuroanatomical sites associated with mood
regulation will be described at the structural and
functional level. Third, the molecular processes that
have been implicated for mediating these structural
and functional changes will be explored. Fourth, the
role of multiple neurotransmitter systems will be
reviewed for their involvement in restoration and
recovery from MDD. The last section will discuss the
treatment guidelines for obtaining remission in the
context of this neurobiological model.
Major depressive disorder
as a progressive illness
Epidemiological studies have consistently shown that
MDD is one of the most prevalent lifetime psychiat-
ric disorders. In the National Comorbidity Replica-
tion Survey, based on DSM-IV criteria for MDD, the
lifetime prevalence rate was 16.2%, with a 12-month
estimate of 6.6% (5). The presentation of MDD is
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ated symptoms (6). In the Diagnostic and Statistical
Manual of Mental Disorders Fourth Edition, Text
Revision (7), the diagnosis of MDD requires the
experience of major depressive episodes that are
deﬁned by at least ﬁve of the following symptoms
for at least 2 weeks duration: loss of interest,
depressed mood, appetite/weight disturbance, sleep
disturbance, psychomotor change, loss of energy,
worthlessness/guilt, concentration difﬁculties/indeci-
siveness and thoughts of death/suicide. Depressed
mood or loss of interest must be one of the symp-
toms, but with the inclusion of compound criteria
(e.g. worthlessness or guilt), a diagnosis of MDD can
be met by various permutations, and episodes may
then be further qualiﬁed by other associated features
(e.g. postpartum, seasonal pattern, with melancholy
or psychotic symptoms).
Even though MDD is characterised as an episodic
illness, prospective studies have found that recur-
rence is the norm rather than the exception. For
example, in a naturalistic, 15-year follow-up of a
sample of 380 patients experiencing an index MDD
episode, 73% experienced a recurrent episode (8),
with each subsequent episode increasing the proba-
bility of further episodes (9). Similarly, in the
STAR*D Project (Sequenced Treatment Alternatives
to Relieve Depression) that includes 1500 patients
with MDD, 74% of patients had experienced more
than one episode (10). Recurrence of MDD appears
to be driven in part by neurobiological vulnerabili-
ties. In the STAR*D Project, patients who experi-
enced multiple episodes were more likely to have a
positive family history of depressive illness and an
earlier age of onset of their index depressive episode
compared with patients who were in their ﬁrst epi-
sode (10).
Consistent evidence has also supported a ‘kindling
hypothesis’ in which depressive episodes become
more easily triggered over time (11). As the number
of depressive episodes increase, future episodes are
predicted more by the number of prior episodes
rather than by life stress (12) (Figure 1). Kindling
can be described as a process which occurs by a low-
ering of the threshold for the impact of stressful life
events (i.e. sensitisation to minor events) or by an
increase in spontaneous dysregulation, both of which
could indicate progressive effects of MDD (13). An
analysis of the risk of recurrence in a large study of
twins also suggests genetic contributions as patients
with a high genetic risk were ‘prekindled’; that is,
they had a lower association between stressful life
events and the onset of depressive episodes compared
with patients having a low genetic risk (14).
Early adverse experiences may also contribute to
long-term neurobiological alterations associated with
depression. In preclinical studies, maternal depriva-
tion of rat pups during critical development periods
resulted in subsequent hyper-reactivity to stress and
marked behavioural changes in adult rats (15). In
children who had a history of early maltreatment,
the risk for depressive symptoms was associated with
an interaction between genotypes [e.g. serotonin
(5-HT) transporter] and history of maltreatment
(16). Considering these ﬁndings, some researchers
have suggested that greater neurobiological changes
occur in patients with depression who have early
adverse experiences compared with patients who are
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Figure 1 Major depression as a progressive illness. As the number of major depressive episodes increase, the risk for
subsequent episodes is predicted more from the number of prior episodes and less from the occurrence of a recent life
stress. Figure adapted from ref. no. (14)
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that these patients may represent an especially vul-
nerable subtype of depressive illness (17).
Chronicity also suggests long-term neurobiological
consequences associated with the MDD illness. In the
STAR*D Project, 25% of the patients (with single or
recurrent MDD) were identiﬁed as having a chronic
episode of more than 2 years duration (10). In
another large multicentre treatment study (n ¼ 681),
patients’ depression was classiﬁed using DSM-IV
modiﬁers into four categories: chronic MDD (epi-
sodes > 2 years), MDD with incomplete recovery
(partial response), MDD superimposed on dysthymia
(double depression) and chronic MDD superimposed
on dysthymia (depressive symptoms > 4 years).
Despite multiple comparisons across a broad range
of clinical and psychological variables, few differences
were found among the four groups, resulting in the
conclusion that various manifestations of chronic
depression represent the same illness (18).
As the duration of depressive episodes increases,
the probability of recovery substantially decreases
over time. In a 5-year prospective study of outpa-
tients with depression, approximately half recovered
within the ﬁrst 6 months, but afterwards the rate of
recovery diminished substantially. For example,
patients who had experienced depressive episodes of
1-year duration had a recovery rate of 16% com-
pared with a 1% recovery rate for patients whose
episodes persisted > 5 years (19). Similarly, in a pro-
spective study of new onset depressive episodes, a
longer duration (> 12 weeks) of previous episodes
reduced the likelihood of recovery from the new
onset episode by 37% (20).
Even if patients no longer meet full criteria for an
MDD episode, studies have found that a substantial
subset of patients continue to experience residual
symptoms and diminished functioning. In a 3-year
longitudinal epidemiological study, 165 patients were
assessed before and after an MDD episode. Although
mean values on functional measures returned to pre-
morbid levels, 15–40% of patients experienced a wors-
ening in psychosocial functioning that persisted after
the episode, and the overall functioning of the entire
sample continued to be lower than that of a healthy
cohort (21). In a 10-year, naturalistic longitudinal
study, patients who experienced subthreshold depres-
sive symptoms following an MDD episode were at
signiﬁcantly greater risk for a recurrence, and they
also had a much faster onset of their next episode
compared with patients whose episode had fully
remitted, suggesting that residual symptoms represent
vulnerability because of an active disease state (22).
The recurrence and chronicity of MDD along with
possible kindling effects have shifted the perspective
of the appropriate treatment goal. The gold standard
for treatment outcome has been raised from response
(reduction in symptoms) to remission (absence of
symptoms) or recovery (extended period of remis-
sion) (23). However, obtaining recovery implies not
only the remission of symptoms but also a restora-
tion of the underlying physiology associated with the
illness. Therefore, further understanding of the neu-
robiological changes associated with MDD is neces-
sary for identifying true recovery processes.
Functional and structural changes
in MDD
Although much information still needs to be
attained, imaging and other methods have begun to
elucidate the neurobiological abnormalities associated
with MDD. In particular, several prefrontal and lim-
bic structures and their interconnected circuits have
been implicated in affective regulation (Figure 2).
These neuroanatomical areas include the ventrome-
dial prefrontal cortex (VMPFC), lateral orbital pre-
frontal cortex (LOPFC), dorsolateral prefrontal
cortex (DLPFC), anterior cingulated cortex (ACC),
ventral striatum (including nucleus accumbens),
amygdala and the hippocampus. Abnormalities in
these areas have been shown in patients with MDD
compared with healthy controls and thus suggest a
foundation for the symptomatic expression of MDD
(24,25). However, these deviations may be obscured
or not present at the individual patient level and
thus, these ﬁndings cannot necessarily be considered
pathognomic.
As an integrated circuit, the prefrontal cortex, cin-
gulate, amygdala, and hippocampus serves not only
mood regulation, but also learning and contextual
memory processes. Within the prefrontal cortex, the
VMPFC mediates pain, aggression, sexual functioning
and eating behaviours whereas the LOPFC assesses
risk and modulates maladaptive and perseverative
affective states (behaviours). These two areas have a
reciprocal pattern of activity with the DLFPC, which
maintains executive function, effortful sustained
attention, and working memory processes (26). Sub-
divisions within the ACC assume diverse roles, with
the dorsal ACC being part of the cognitive/executive
functioning network and the ventral ACC being
involved in assessing emotional and motivational
information. The ACC also monitors outcomes of
behaviour and cognition and makes adjustments
based on changing contingencies (27,28).
In patients with MDD, regional blood ﬂow studies
suggest hyperactivity in the VMPFC and LOPFC
and hypoactivity in the DLFPC compared with con-
trols (24). Given the functions of these regions, as
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may be responsible for the manifestations of symp-
toms associated with MDD. Hyperactivity of the
VMPFC is associated with enhanced sensitivity to
pain, anxiety, depressive ruminations and tension
whereas hypoactivity of the DLFPC may produce
psychomotor retardation, apathy, and deﬁcits in atten-
tion and working memory. Using fMRI paradigms,
connectivity studies have also suggested a decrement
in the ‘communication’ between amygdala and ACC
regions (29). A consequence of this loss of connectivity
could be a failure of the ACC to serve its inhibitory
role in emotional regulation (30), resulting in further
motivational and affective disruption (31).
At the intersection of limbic, cognitive/executive
and neuroendocrine regulatory circuits, including the
hypothalamic-pituitary-adrenal axis (HPA), the hip-
pocampus may be particularly vulnerable in depres-
sion. Imaging studies of hippocampal volume have
been of particular interest. In a meta-analysis of 12
studies, hippocampal volume was found to be consis-
tently and signiﬁcantly reduced in patients with
MDD compared with controls, and these reductions
occurred bilaterally with a slightly greater decrement
in right hippocampal volume (32). Other studies
have shown that the degree of hippocampal reduc-
tion is directly proportional to the number and the
duration of untreated depressive episodes (33).
Among depressed inpatients, while controlling for
the effect of age, hippocampal volume was signiﬁ-
cantly correlated with duration of illness prior to
hospitalisation (34). Even after remission of an epi-
sode, patients with recurrent MDD have continued
to show signiﬁcantly smaller hippocampal volume
compared with healthy controls (35).
Differences in hippocampal volume between
patients with depression and healthy controls may
not be fully attributable to the disease state. Herita-
bility studies of hippocampal volume suggest both
environmental and genetic contributions with herita-
bility estimates of 54% in nonhuman primates and
40% in adult male twins (36,37). Several genomic
imaging studies, comparing patients with MDD and
healthy controls, have shown associations between
hippocampal volume and speciﬁc genes that are
implicated in mood disorders (38,39). In a 1-year
prospective study of 30 patients with MDD, hippo-
campal volume did not signiﬁcantly change during
the study period, but patients whose depression
failed to remit had a signiﬁcantly smaller hippocam-
pus at baseline and at 1 year than did patients who
did remit (40). Combining the evidence from these
genetic, cross-sectional, and clinical treatment studies
suggests that morphological differences in the
hippocampus may be a predisposing factor in MDD,
but changes can also accumulate in the course of the
disease and thereby create an obstacle to full
recovery.
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Figure 2 Major depressive disorder affects the dynamic connectivity among neuroanatomical structures involved in
regulation of mood and stress response. Limbic structures (amygdala, hippocampus and nucleus accumbens) have
reciprocal connections with ‘para-limbic’ cortical areas, subgenual anterior cingluate and ventromedial prefrontal cortex
(VMPFC). Hypothetically, disrupted ‘connectivity’ between limbic/para-limbic areas and rostral integrative prefrontal
formations, results in compromised feedback regulation of limbic activity. Consequently, dorsal cognitive/executive
network is hypoactive while overly active limbic areas continue to stimulate the hypothalamus leading to neuroendocrine
dysregulation and sympathetic hyperactivity
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neurobiological changes
The alteration in the hippocampus signiﬁes a poten-
tial outcome of injurious feedback that occurs via
neuroendocrine dysregulation. A consistent ﬁnding
in patients with MDD is a high level of the stress
hormone cortisol, which may cause impairment in
neuroplasticity and cellular resistance (41). An imbal-
ance between glucocorticoid and mineral corticoid
receptors in MDD along with high-density glucocor-
ticoid receptors (GRs) may also contribute to the
hippocampus’ susceptibility to neuronal damage
(42). Subsequent hippocampal atrophy could result
in further neuroendocrine dysfunction and hence a
potential ‘run-away’ system (43). Postmortem com-
parisons of brain tissue in patients with MDD and
age-matched healthy controls have shown hippocam-
pal shrinkage in depressed subjects that was caused
by increased density of neuronal cells and a signiﬁ-
cant reduction in neuropil (i.e. decreased dendridic
branching and spine complexities) (44).
A corollary of elevated glucocorticoids and com-
promised hippocampal functioning may also be the
down-regulation of the GR sensitivity. Under condi-
tions of chronic stress, decrease in GR sensitivity can
have negative consequences as GR signalling becomes
insufﬁcient to ‘turn off’ the initial responses to stress
as part of a negative feedback process (45,46)
(Figure 3). Subsequently, HPA hypothalamic overac-
tivity, in conjunction with amygdala activation, leads
to increased sympathetic tone, which promotes the
release of cytokines from macrophages. Increase in
pro-inﬂammatory cytokines has been associated with
loss of insulin and GR sensitivity, which further
perpetuates metabolic and neuroendocrine disruption
(47). Symptomatically, disruptions as a result of
proinﬂammatory cytokines may be experienced as
fatigue, loss of appetite and libido as well as hyper-
sensitivity to pain (48).
Proinﬂammatory cytokines may also diminish
neurotrophic support and monoamine neurotrans-
mission that can lead to neuronal apoptosis and glial
damage. Alterations in glia–neuron relationships have
been recently emphasised in the aetiology of neuro-
pathic pain and MDD (47,49). Glia cells are involved
in an intricate interaction with neurons in which
astroglia and microglia maintain homeostasis of the
Figure 3 Molecular processes are impacted by stress and depression. Stress results in release of glucocorticoids and
corticotrophin releasing hormones (CRH) and pro-inﬂammatory cytokines (TNF, IL-1, IL-6). In depression, disruption of
serotonin (5-HT), norepinephrine (NE) and dopamine (DA) transmission impair the regulatory feedback loops that ‘turn
off’ the stress response. Sympathetic overactivity contributes to immune activation and release of inﬂammatory cytokines.
Inﬂammatory cytokines further interfere with monoaminergic and neurotrophic signalling. They may also diminish central
corticosteroid receptor sensitivity, leading to disruption of feedback control. Figure adapted from ref. no. (46)
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neurotransmitters, cytokines and neurotrophic fac-
tors (50). Neurons reciprocate support of glial func-
tion via neurotrophin signalling. Stress, depression
and ensuing peripheral immune dysregulation lead
to activation of microglia that then contribute to the
existing immune disruption by additional release of
inﬂammatory cytokines (51).
An integral part of maintaining the health of these
glial–neuron interactions may be mediated by brain-
derived neurotrophic factor (BDNF) (52). Involved
in neurogenesis, BDNF is the primary neurotrophin
of the hippocampus. As a dimeric protein involved
in cell maintenance, plasticity, growth and death
(apoptosis), BDNF is structurally related to nerve
growth factor and is distributed widely throughout
the brain (53). When BDNF interacts with tyrosine
receptor kinase receptors (TRkB), it promotes cellu-
lar resilience and long-term potentiation. However,
the precursor form of BDNF (pro-BDNF) can also
precipitate reduction in dendritic spines and cell
death when it binds with the p75 receptor. Thus,
depending upon its expression, BDNF can prune
neural networks in an activity dependent manner
that is regulated by various neurotransmitters [gluta-
mate, GABA, 5-HT, norepinephrine (NE), acetylcho-
line, dopamine and hormones] (54).
Preclinical and clinical studies have suggested dys-
regulation in BDNF occurs under conditions of
chronic stress and depression. In animal models,
acute and chronic immobilisation stress resulted in
decreased BDNF expression using mRNA assays.
Similar results were also observed following adminis-
tration of acute and chronic pain stimuli (55).
Within humans, levels of serum BDNF has been
found to be signiﬁcantly lower in untreated patients
with MDD compared with treated patients or healthy
controls (56). Similarly, postmortem analyses of
brains of persons who committed suicide showed
that BDNF and another neurotrophin (NT-3) were
signiﬁcantly reduced compared with non-suicide
controls (57).
From the above observations, the neurotrophic
hypothesis has emerged as a major theory for the
pathogenesis of major depression. In this model,
stress and genetic vulnerability elevate glucocorticoid
steroids and alter cellular plasticity via downregula-
tion of growth factors and receptor sensitivity (4).
The reduction in growth factors, such as BDNF,
impacts negatively on the structural and functional
processes within the limbic system, especially for the
hippocampus. Chronic and recurrent MDD may
result in subsequent atrophy and further disruptions
in neurocircuitry. From this hypothesis, recovery and
remission of MDD would be dependent upon a
reversal of these processes, such as an increase in
BDNF levels.
Complementing the neurotrophic hypothesis of
MDD is the monoamine theory, which postulates
that depression is associated with low levels of
monoamines, particularly, 5-HT and NE. A recent
imaging study of patients with untreated depression
found a high global receptor density for the mono-
amine oxidase A (MAO-A), which nonspeciﬁcally
metabolises these neurotransmitters. In this updated
theory, long-term monoamine loss because of this
global MAO-A activity interacts with regional speciﬁc
transporter densities (i.e. 5-HT, NE), resulting in the
expression of the depressive illness (58). Both 5-HT
and NE ascending ﬁbres originate from brainstem
nuclei and innervate the limbic system, prefrontal
cortex and associated structures involved in the regu-
lation of mood. Descending pathways project
through the dorsolateral spinal column and are
instrumental in the regulation of pain (59,60). There-
fore, depending upon the speciﬁc transporter densi-
ties within these regions, various symptoms of
depression (mood, cognition and pain) will be mani-
fested within the context of the overall global reduc-
tion in monoamine levels (58).
Role of neurotransmitters in recovery
from MDD
Therapeutically, selective serotonergic reuptake inhib-
itors (SSRIs) and NE reuptake inhibitors (NRIs) are
known to increase their respective monoamine levels
in the brain. Chronic treatment with monoamine
reuptake inhibitors increases activation of cyclic
adenosine 3-5 monophosphatase (cAMP), which in
turn stimulates protein kinase A. Activation of this
protein enzyme regulates target genes leading to an
increase in BDNF synthesis (52). The antidepressant-
induced cAMP activity can also enhance GR sensitiv-
ity and inhibit cytokine signalling, further assisting
in the restoration of the neurocircuitry feedback
loops (61).
The effect of increasing monoamine levels (dopa-
mine, 5-HT and NE) on BDNF and growth factors
may be one mechanism that produces the antide-
pressant response. Preclinical study of rat brain cells
has demonstrated that monoamenergic activity (NE,
5-HT) upregulates BDNF synthesis in astrocytes
(62). Clinically, successful treatment with antidepres-
sants results in normalisation of serum BDNF level,
which is considered an indirect measure of cortical
BDNF activity. Support for the relationship between
serum and cortical BDNF levels has been derived
from correlations in animal studies as well as ﬁnd-
ings that serum BDNF passes the blood–brain barrier
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(63,64). In a study of 10 patients who were treated
for 12 weeks with a dual reuptake inhibitor,
improvement in depressive symptoms was correlated
with increases in BDNF levels, and the BDNF levels
of remitted patients had normalised to the same level
observed in healthy controls (65). Response to vari-
ous SSRI and 5-HT noradrenalin reuptake inhibitors
(SNRI) treatments has been similarly associated with
restoration of normative BDNF values (66) (Fig-
ure 4). Postmortem analysis of brain tissue has
shown that subjects who had been treated with an
antidepressant at time of death had greater hippo-
campal BDNF expression as measured by immunore-
activity than did untreated subjects with mood
disorders (67).
Antidepressant therapeutic response is also associ-
ated with re-establishment of normative cortical
activity. A study of 17 inpatients with MDD exam-
ined regional activity changes following 1 week and
6 week ﬂuoxetine treatment. At 1 week, all patients
showed increases in hippocampal activity and
decreases in posterior cingulate and prefrontal cortex
activity. After 6 weeks of treatment, patients who
had responded to treatment showed a reversal of this
pattern with decreased limbic activity and increased
prefrontal cortical activity whereas non-responders
continued to show the 1-week pattern (68). Normali-
sation in the amygdala and ACC has also been asso-
ciated with positive response to treatment. Using a
masking paradigm for subconscious activation,
patients with MDD showed a baseline hyper-reactiv-
ity of the left amygdala that attenuated following
8-week treatment with sertraline (69).
Other lines of evidence also support the restorative
nature of antidepressant therapy. Structural and
functional MRI assessments of patients with MDD
who were treated with ﬂuoxetine indicated the
importance of ACC grey matter volume for treat-
ment response as there was a positive association
among grey matter volume, normalisation of ACC
activity, and response to treatment (70). Conversely,
in patients with MDD who failed to respond to anti-
depressant treatment, plasma levels of proinﬂamma-
tory cytokines were elevated compared with healthy
controls or euthymic patients with MDD (71).
Symptomatically, improvements in speciﬁc MDD
symptoms have been associated with regional
improvements in brain metabolic activity. In 39 out-
patients with MDD, improvement in cognitive symp-
toms was correlated with increases in DLPFC and
improvements in fatigue/psychomotor retardation
was associated with decreases in VMPFC activity.
Interestingly, these changes were seen in responders
regardless of whether treatment was pharmacological
or psychological (72). Restoration of the neurobio-
logical regulation in MDD via neurotrophic factors
and neurogenesis appears to be a common factor
across various effective treatments for MDD, includ-
ing pharmacological, psychological and somatic treat-
ments, such as diet and exercise (73).
Treatment implications of the
neurobiological model
The neurobiological sequelae and repercussions of
chronic or recurrent MDD indicate that interventions
for MDD should be focused on achieving optimal
treatment early. Longitudinal studies have shown that
one of the best predictors of remission status at
2 years was response to acute treatment, i.e. initial
6 weeks (74). In addition, the adequacy of treatment
may also have prognostic implications. For patients
with late-life depression, exposure to previous inade-
quate trials of antidepressants resulted in a reduced
response rate to pharmacological intervention aug-
mented by psychotherapy compared with treatment
of naive patients, even after controlling for baseline
severity (75). Similarly, in a large observational study
of 996 patients with MDD, non-response or incom-
plete response to initial antidepressant treatment was
a signiﬁcant predictor of eventual treatment resis-
tance (76). On the positive side, an early response to
antidepressants has been shown to predict greater
treatment adherence (77).
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Figure 4 Antidepressant therapy is associated with restoring
normative processes. Treatment with various selective
serotonin antidepressant treatments and serotonergic
noradrenergic reuptake inhibitors resulted in increases in
serum brain-derived neurotrophic factor (BDNF) for
patients with MDD to levels comparable that were observed
with healthy controls. Reprinted with copyright permission
from ref. no. (66)
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a comprehensive treatment that increases activity of
multiple monoaminergic systems. In a double-blind,
randomised treatment study, 39 inpatients with
MDD received either ﬂuoxetine (a serotonergic inter-
vention), desipramine (a noradrenergic intervention)
or their combination. After 6 weeks of treatment,
patients who had been given the combination treat-
ment were more likely to achieve remission (53.8%)
than either intervention alone (0 % and 7.1%) (78).
Similarly, a recent large meta-analysis encompassing
93 trials and 17,036 patients compared efﬁcacy out-
comes of SSRI with SNRI treatments for MDD that
showed a modest but signiﬁcant advantage in efﬁcacy
with SNRI treatments (79). An earlier meta-analysis
did not ﬁnd a difference in efﬁcacy between SSRIs
and dual acting agents (mostly tricyclic antidepres-
sants), with the exception of the inpatient popula-
tions, where dual acting tricyclic antidepressants had
an advantage (80). Thus, although current treatment
algorithms for MDD usually are initiated with SSRIs,
the role of combination treatment or dual reuptake
inhibitors are increasingly being considered as a pre-
ferred option (81).
Another advantage of targeting both of 5-HT and
NE systems is improvement not only in the core fea-
tures of MDD, but also in associated physical symp-
toms. Painful physical symptoms are prevalent in
patients with MDD, and these symptoms increase
the illness burden and impair the ability to attain
remission (82,83). In a study of primary care patients
with MDD who were treated with SSRIs for
9 months, mood symptoms continued to improve
over time while painful physical symptoms persisted
(84). The occurrence of painful physical symptoms
and MDD reﬂects the shared underlying pathophysi-
ology between mood and pain regulation. Impor-
tantly, there may be also a synergistic interaction
between the 5-HT and NE systems to obtain analge-
sia. In an animal model of pain, treatment with dual
reuptake inhibitors or combination treatment (5-HT/
NE) appeared to enhance the effectiveness of pain
alleviation (85). Clinically, patients with MDD who
experienced a 50% or greater reduction in pain were
more likely to achieve remission than patients whose
pain reduction was < 50% (86).
With remission and recovery as the goal, the treat-
ment guidelines derived from the neurobiological
model emphasise the need for not only early and
comprehensive intervention, but also vigorous atten-
tion to residual symptoms. In a 2-year study of out-
patients with MDD, patients who obtained only a
partial remission of symptoms were more likely to
relapse (67.5%) than patients who had attained full
remission (15.2%) (87). Speciﬁc recommendations
for the treatment of residual symptoms have not
been determined empirically, but likely require addi-
tional augmentation with other pharmacological and
psychological treatments; in addition to reducing the
risk of relapse, the treatment of residual symptoms
may enhance compliance and long-term outcomes
(88).
Conclusions
As the underlying neurobiological model of depres-
sion is increasingly understood, treatment providers
are directed to recognise that the factors that may
initiate a MDD episode and those that maintain the
illness are likely to be very different. Genetic and
stress vulnerabilities interplay to initiate a cascade of
neurobiological alterations that disrupt a dynamic
system. Progressive effects of recurrent and chronic
MDD may then be potentiated by further structural
and functional abnormalities.
Given these long-term consequences, an essential
objective of treatment must be to restore normative
functioning and prevent further neurobiological
structural alterations. Increasing 5-HT and NE neu-
rotransmission is likely to initiate true recovery with
the restoration of neurotrophic support, glucocorti-
coid signalling and neuroendocrine regulation. The
use of dual reuptake inhibitors enhances the proba-
bility of remission as it addresses the complex inter-
play of the emotional and physical symptoms of
MDD. Painful physical symptoms are increasingly
recognised as having a signiﬁcant impact on func-
tioning and recovery; thus, afﬁrming the need for
antidepressant treatments that can effectively reduce
these symptoms as well.
From the neurobiological model, the treatment
guidelines of early, comprehensive and progressive
treatment require a change in perspective for both
patients and providers. A residual symptom may be
interpreted as a proxy of an active disease state, with
ensuing structural alterations and systemic conse-
quences. With remission and recovery as the goal,
patients will need to be educated about the beneﬁts
of long-term treatment rather than episodic or
incomplete intervention. A biopsychosocial treatment
model that incorporates cognitive-behavioural or
interpersonal therapy along with pharmacological
interventions serves to address both the initiation
and maintenance factors and can reduce the risk of
relapse (89). Once remission is attained, maintenance
of effect may become the more appropriate term,
rather than relapse prevention, to emphasise the
necessity for an ongoing collaboration between
patient and physician in order to maintain neurobio-
logical homeostasis.
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